FDA-cleared profile

NeuroICH

Neurocareai Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.

Clinical role
Notification and triage support operating in parallel with, and independent of, the standard-of-care workflow.
Images and patients
CT/CTA · Brain, with intracranial hemorrhage (ICH) subtypes including extradural, subdural, subarachnoid, intraparenchymal, and intraventricular hemorrhage.
Key limitation
Keep in mind: Notification and preview are informational and non-diagnostic; clinicians must review high-quality images on a diagnostic viewer and complete patient evaluation. The device does not alter or remove the original image, is not a substitute for standard of care, and must not be relied on to make or confirm a diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain, with intracranial hemorrhage (ICH) subtypes including extradural, subdural, subarachnoid, intraparenchymal, and intraventricular hemorrhage. Input: DICOM-compatible non-contrast CT images of the head acquired in the acute setting, including stroke-protocol studies analyzed for suspected ICH.
  • Who uses it?Intended users: Hospital networks and trained clinicians, including neurovascular and neurosurgical specialists responsible for reviewing high-quality images and making care decisions.
  • What does the software produce?Output: Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.
  • What is its most important limitation?Key limitation: Notification and preview are informational and non-diagnostic; clinicians must review high-quality images on a diagnostic viewer and complete patient evaluation. The device does not alter or remove the original image, is not a substitute for standard of care, and must not be relied on to make or confirm a diagnosis.

Clinical takeaway. Clinical role: Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.

Evidence takeaway. Evidence from the reviewed source record: FDA K241719 reports a retrospective blinded study of 376 NCCT head studies, 35.90% ICH-positive and 64.09% normal, with ground truth from three U.S. board-certified neurologists. Primary sensitivity was 94.81% (95% CI 89.68%-97.43%), specificity 92.53% (88.50%-95.21%), accuracy 93.35% (90.37%-95.45%), and AUC 0.9367. A separate secondary workflow analysis used 128 eligible scans and reported time-to-notification of 0.37 +/- 0.20 minutes versus 18.3 +/- 14.2 minutes for standard-of-care time-to-open-exam.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Notify hospital-network clinicians and neurovascular or neurosurgical specialists of suspected ICH on acute non-contrast head CT in parallel with standard-of-care interpretation; it is not a diagnostic device.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Notification and triage support operating in parallel with, and independent of, the standard-of-care workflow.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM-compatible non-contrast CT images of the head acquired in the acute setting, including stroke-protocol studies analyzed for suspected ICH.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Hospital-network acute stroke and parallel workflow; non-contrast head CT images are acquired in the acute setting.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Hospital networks and trained clinicians, including neurovascular and neurosurgical specialists responsible for reviewing high-quality images and making care decisions.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Notification and preview are informational and non-diagnostic; clinicians must review high-quality images on a diagnostic viewer and complete patient evaluation. The device does not alter or remove the original image, is not a substitute for standard of care, and must not be relied on to make or confirm a diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K241719 reports a retrospective blinded study of 376 NCCT head studies, 35.90% ICH-positive and 64.09% normal, with ground truth from three U.S. board-certified neurologists. Primary sensitivity was 94.81% (95% CI 89.68%-97.43%), specificity 92.53% (88.50%-95.21%), accuracy 93.35% (90.37%-95.45%), and AUC 0.9367. A separate secondary workflow analysis used 128 eligible scans and reported time-to-notification of 0.37 +/- 0.20 minutes versus 18.3 +/- 14.2 minutes for standard-of-care time-to-open-exam.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K241719 reports a retrospective blinded study of 376 NCCT head studies, 35.90% ICH-positive and 64.09% normal, with ground truth from three U.S. board-certified neurologists. Primary sensitivity was 94.81% (95% CI 89.68%-97.43%), specificity 92.53% (88.50%-95.21%), accuracy 93.35% (90.37%-95.45%), and AUC 0.9367. A separate secondary workflow analysis used 128 eligible scans and reported time-to-notification of 0.37 +/- 0.20 minutes versus 18.3 +/- 14.2 minutes for standard-of-care time-to-open-exam.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
94.81% (95% CI: 89.68%, 97.43%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
92.53% (95% CI: 88.50%, 95.21%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

NeuroICH regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K241719
  • Samplen=376
  • IndependenceIndependence not established

K241719

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241719. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compatible non-contrast CT images of the head acquired in the acute setting, including stroke-protocol studies analyzed for suspected ICH.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K241719: NeuroICH

  2. Routing

    Source context, not route validation: The packet describes a cloud-hosted image-analysis module, DICOM-compatible acquisition, and mobile-app preview/notification. It does not establish a specific PACS, RIS, EHR, or routing interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K241719: NeuroICH

  3. AI processing

    Source context, not route validation: The exact FDA package describes an image analysis module hosted on cloud and a mobile application for previewing notifications, with images sent from the local hospital network to a remote location for storage, processing and analysis. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "NeuroICH mainly consists of an image analysis module hosted on cloud, and a mobile application for preview of notification and non-diagnostic images." … "use the similar process of automatic data identification and transfer to send images from the local hospital network to a remote location for image storage, processing and analysis.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K241719: NeuroICH

  4. Returned objects

    Source context, not route validation: Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K241719: NeuroICH

  5. Viewer/worklist/report

    Unresolved route: Detection of suspected ICH and a notification with non-diagnostic preview images sent to a mobile application; the device does not mark or segment the original image and does not remove cases from the worklist.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K241719: NeuroICH

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes an image analysis module hosted on cloud and a mobile application for previewing notifications, with images sent from the local hospital network to a remote location for storage, processing and analysis. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "NeuroICH mainly consists of an image analysis module hosted on cloud, and a mobile application for preview of notification and non-diagnostic images." … "use the similar process of automatic data identification and transfer to send images from the local hospital network to a remote location for image storage, processing and analysis.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The packet describes a cloud-hosted image-analysis module, DICOM-compatible acquisition, and mobile-app preview/notification. It does not establish a specific PACS, RIS, EHR, or routing interface.
  • Exact FDA submission
  • Checked 2026-09-08
Security
The SaveLife.AI trust center (SaveLife.AI is the d/b/a of applicant Neurocareai, Inc.) states HITRUST CSF Certified and HIPAA Compliant status, with a third-party HIPAA audit report and HITRUST CSF assessment report available under NDA; the page also cites FDA 510(k) K241719.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statements, not attestations. The reports are NDA-gated and were not read; the trust center cites K241719 (NeuroICH) but does not scope the claims to any specific release; exact-release scope is not established.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for NeuroICH; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241719
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Brain, with intracranial hemorrhage (ICH) subtypes including extradural, subdural, subarachnoid, intraparenchymal, and intraventricular hemorrhage.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-11-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K241719 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K241719: NeuroICH

    U.S. Food and Drug Administration - Published 2024-11-07 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. NeuroICH model card (K241719)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K241719

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. SaveLife.AI: Security & Trust Center

    Neurocareai, Inc. (d/b/a SaveLife.AI) - Accessed 2026-10-27

    Scope: security

Research history

  1. K241719 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24
FDA-cleared K251983

Brainomix 360 Triage Stroke

Brainomix Limited

Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.

Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Decision
2025-08-26
FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history